Goldman Sachs tips NextDC share price to rise 40%

Goldman Sachs is bullish on this data centre operator's shares..

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The NextDC Ltd (ASX: NXT) share price is having a tough week.

Despite releasing a strong full year result, weakness in the tech sector has dragged the data centre operator's shares lower.

Man on a tablet in a room with data centre technology.

Image source: Getty Images

Is the NextDC share price weakness a buying opportunity?

According to a note out of Goldman Sachs, its analysts believe investors should be snapping up shares following recent weakness.

This morning its analysts have retained their conviction buy rating with an improved price target of $14.30.

Based on the current NextDC share price of $10.26, this implies potential upside of almost 40% for investors over the next 12 months.

What did the broker say?

Goldman was pleased with NextDC's "solid" result and was even happier with its guidance for FY 2023. The broker commented:

NXT reported a solid FY22 result, with revenue/EBITDA -1% vs. GSe, but within/above its upgraded guidance range. Positively FY23 Rev/EBITDA guidance for +19%/+15% growth was provided, which was +1% vs. Gse.

Its analysts were also pleased to see that NextDC demonstrated good pricing power with its services, which helped offset inflationary pressures. It explained:

Other Positives: (1) Pricing power evident, with strong realized yields & 5-7% price rises introduced given inflation/power; (2) High yielding Enterprise momentum across all regions, with +3MW contracted growth in FY22, at top end of historical targets; (3) M2 Expansion to 100MW (from 60).

All in all, this has led to Goldman making small upgrades to its earnings estimates and its valuation. It concludes:

We revise NXT FY23-24 EBITDA +2%/+0% given stronger yields, offset by higher costs. Our 12m TP is +1% to $14.30. Stay Buy (on CL) ahead of the acceleration in growth following S3/M3 openings and supply chain normalization.

Motley Fool contributor James Mickleboro has positions in NEXTDC Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Man drawing an upward line on a bar graph symbolising a rising share price.
Broker Notes

Broker says this ASX 200 stock could rocket 50%+ in 12 months

Bell Potter has good things to say about this stock.

Read more »

Broker Notes

2 ASX 200 stocks drawing fresh buy ratings this week 

These shares have solid upside.

Read more »

Time to sell written on a clock.
Broker Notes

Sell alert! Why this expert is calling time on Magellan and Ramsay Health Care shares

A leading expert forecasts growing headwinds for Magellan and Ramsay Health Care shares. But why?

Read more »

Pilot on the phone looking distraught.
Broker Notes

Sell alert! Why this expert is ditching Qantas shares for this ASX 200 defence stock

A leading expert is selling Qantas shares and buying this surging ASX 200 defence stock instead. But why?

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Broker Notes

Morgans tips a 600%+ return for this ASX biotech stock

Good clinical study progress has the broker bullish on this company.

Read more »

Wlorker on a laptop on top of solar panels.
Broker Notes

Up 8%, should I buy the rebound in Origin Energy shares today?

A leading analyst provides his forecast for Origin Energy’s rebounding shares.

Read more »